INSM
HealthcareInsmed Incorporated
$175.20
$-1.92 (-1.08%)
Jan 5, 2026
Price History (1Y)
Analysis
Insmed Incorporated is a biotechnology company operating in the healthcare sector. With a market capitalization of $37.37 billion, it is a significant player in its industry. The company employs 1,271 individuals, indicating a substantial scale of operations. Insmed's revenue for the trailing twelve months (TTM) stands at $447.02 million. The company's financial health is marked by negative profitability metrics. Gross margin is reported to be 76.5%, while operating and profit margins are significantly lower, at -183.6% and -264.8%, respectively. Returns on equity and assets are also negative, standing at -165.7% and -28.0%, respectively. The balance sheet shows a debt-to-equity ratio of 78.27, which is substantial. However, the company has a sizeable cash reserve of $1.68 billion against a debt of $740.13 million. Insmed's valuation context is characterized by negative price-to-earnings (TTM) and forward P/E ratios, at N/A and -49.84, respectively. The price-to-book ratio stands at 39.39, while the price-to-sales metric is significantly higher, at 83.59. Revenue growth for the year-over-year period is reported to be 52.4%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Insmed Incorporated
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Visit website →Key Statistics
- Market Cap
- $37.37B
- P/E Ratio
- N/A
- 52-Week High
- $212.75
- 52-Week Low
- $60.40
- Avg Volume
- 2.84M
- Beta
- 1.09
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 1,271